Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.20.2
Consolidated Balance Sheets - USD ($)
May 31, 2020
Nov. 30, 2019
Current Assets    
Cash and cash equivalents $ 8,419,565 $ 6,541,037
Marketable securities 905,429 904,053
Accounts receivable (net of allowance for doubtful accounts of $2,763,923 and $2,584,091, respectively) 5,974,457 6,097,331
Prepaid expenses 684,875 500,260
Inventory, current portion 1,053,835 1,084,533
Other current assets 241,878 260,397
Total current assets 17,280,039 15,387,611
Property and Equipment-net 1,738,624 1,846,467
Other Assets    
Intangible assets, net 1,215,421 1,249,254
Inventory, net of current portion 12,382,936 12,646,000
Goodwill 1,941,411 1,941,411
Deferred tax assets 9,079,994 9,079,994
Operating lease right-of-use asset 431,424  
Deposits and other assets, net 462,763 427,423
Total other assets 25,821,949 25,652,082
Total assets 44,840,612 42,886,160
Current Liabilities    
Accounts payable 951,852 1,369,111
Accrued expenses 1,938,826 2,085,180
Current portion of note payable 3,100,000 3,100,000
Current portion of operating lease liability 268,341  
Deferred revenue 8,839,718 8,875,138
Total current liabilities 15,098,737 15,429,429
Other Liabilities    
Deferred revenue, net of current portion 25,312,382 23,633,373
Contingent consideration 3,471,068 3,495,057
Note payable, net of current portion and debt issuance costs 4,352,971 5,856,152
Operating lease long-term liability 163,249  
Long-term liability—revenue sharing agreements 1,425,000 1,425,000
Total other liabilities 34,724,670 34,409,582
Total liabilities 49,823,407 49,839,011
Commitments and contingencies (Note 10) 0 0
Stockholders' Deficit    
Preferred stock 0 0
Common stock ($.01 par value, 20,000,000 authorized; 13,633,638 issued and 7,545,613 outstanding as of May 31, 2020 and 13,598,909 issued and 7,510,884 outstanding as of November 30, 2019) 136,336 135,989
Additional paid-in capital 36,248,232 35,918,827
Treasury stock, at cost (20,563,357) (20,563,357)
Accumulated deficit (20,804,006) (22,444,310)
Total stockholders' deficit (4,982,795) (6,952,851)
Total liabilities and stockholders' deficit 44,840,612 42,886,160
Series A Junior Participating Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 308,000 $ 308,000